Having identified Src, ERK, and CDK2/4 as upstream kinases that inhibit the tumor suppressor function of APCCdh1, here we explore the combinational treatment of TNBC cells using Src inhibitor dasatinib and MEK inhibitor PD0325901, both of which only displayed moderate efficacy in suppressing TNBC cells survival (IC50 at about 1–4 μM). This evidence concerns the gene CDK2 and neoplasm.